MedTrace Logo

THINC-it Vortioxetine - Sensitivity to Change

NCT03053362 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2025-06-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the sensitivity of the THINC-it tool, in measuring change in cognitive deficits in individuals with MDD after receiving vortioxetine.

Conditions

Interventions

DRUG

Vortioxetine

Observing change in cognition using THINC-it tool in patients with MDD.

OTHER

THINC-it Tool

Digitalized cognitive test application administering the following cognitive test components: Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)

Sponsors & Collaborators

  • Brain and Cognition Discovery Foundation

    lead OTHER

Principal Investigators

  • Roger McIntyre · Brain and Cognition Discovery Foundation

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2018-08-08
Completion
2018-08-08
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03053362 on ClinicalTrials.gov